Table 5.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Kidney Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		9,738	10,360	10,645	11,072	11,382	11,693	12,418	12,696	13,542	14,226
Tx with Antirejection Treatments		3,654	3,956	3,363	4,318	5,838	3,445	2,649	2,439	2,393	2,394
Antibodies	Category Usage	53.0%	57.2%	53.4%	32.1%	16.8%	27.1%	36.9%	36.9%	35.5%	37.2%
	ALG	19.5%	20.6%	18.7%	5.8%	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.7%	0.4%	0.8%	2.1%	2.8%	5.8%	7.0%	4.9%	2.8%	2.7%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.2%	0.6%	0.7%	1.1%	1.1%	0.1%	0.0%
	OKT3	39.3%	43.9%	43.0%	26.5%	13.9%	21.6%	26.2%	18.7%	14.6%	11.4%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.1%	0.2%	0.9%	7.8%	12.9%	17.8%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	3.4%	5.8%	3.4%	2.9%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	1.6%	4.0%	5.0%
Corticosteroids	Category Usage	80.7%	81.0%	78.7%	58.0%	38.4%	58.5%	78.6%	78.6%	80.0%	80.5%
	Steroids	80.7%	81.0%	78.7%	58.0%	38.4%	58.5%	78.6%	78.6%	80.0%	80.5%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.